205 related articles for article (PubMed ID: 35860247)
1. Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure.
Lin X; Song A; Lu J; Zheng S; Hu Z; Ma L; Cao Z; Li H; Zheng Y; Ren S; Chen X
Front Immunol; 2022; 13():879835. PubMed ID: 35860247
[TBL] [Abstract][Full Text] [Related]
2. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation.
Guo Y; Han J; Zhang Y; Jin C; Zhang Y; He J; Chen S; Guo Y; Lin Y; Li F; Yang F; Shen Z; Mao R; Zhu H; Zhang J
Front Cell Infect Microbiol; 2023; 13():1120300. PubMed ID: 36909726
[TBL] [Abstract][Full Text] [Related]
3. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients.
Wang WX; Jia R; Gao YY; Liu JY; Luan JQ; Qiao F; Liu LM; Zhang XN; Wang FS; Fu J
Front Immunol; 2022; 13():894410. PubMed ID: 35958609
[TBL] [Abstract][Full Text] [Related]
4. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
[TBL] [Abstract][Full Text] [Related]
5. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
[TBL] [Abstract][Full Text] [Related]
6. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
7. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B.
Lee SK; Kwon JH; Lee SW; Jang JW; Nam H; Baik KW; Yoo SH; Nam SW; Sung PS; Bae SH; Choi JY; Yoon SK
Liver Int; 2021 Feb; 41(2):288-294. PubMed ID: 33043567
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.
Zhao Q; Liu H; Tang L; Wang F; Tolufashe G; Chang J; Guo JT
Antiviral Res; 2024 Jan; 221():105782. PubMed ID: 38110058
[TBL] [Abstract][Full Text] [Related]
9. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B.
Ren H; Huang Y
J Viral Hepat; 2019 Jul; 26 Suppl 1():5-31. PubMed ID: 31380584
[TBL] [Abstract][Full Text] [Related]
10. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
12. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.
Qi W; Zhang Q; Xu Y; Wang X; Yu F; Zhang Y; Zhao P; Guo H; Zhou C; Wang Z; Sun Y; Liu L; Xuan W; Wang J
J Viral Hepat; 2020 Apr; 27(4):387-396. PubMed ID: 31755220
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
14. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
15. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
16. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol.
Zhu S; Wu L; Mei Y; Liu Z; Lin L; Yuan J; Li J; Li X; Peng L
BMJ Open; 2021 Oct; 11(10):e049104. PubMed ID: 34697111
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues.
Manolakopoulos S; Kranidioti H; Kourikou A; Deutsch MM; Triantos C; Tsolias C; Manesis EK; Mathou N; Alexopoulou A; Hadziyannis E; Papatheodoridis G
Liver Int; 2021 Jan; 41(1):48-57. PubMed ID: 33373114
[TBL] [Abstract][Full Text] [Related]
18. What will it take to cure hepatitis B?
Jeng WJ; Lok ASF
Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972391
[TBL] [Abstract][Full Text] [Related]
19. [Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance].
Lin X; Wang XX; Song AX; Lu JF; Liu YL; Jin Y; Cao ZH; Ma LN; Zheng YY; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):673-678. PubMed ID: 34371538
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.
Lee D; Chung YH; Kim JA; Park WH; Jin YJ; Shim JH; Ryu SH; Jang MK; Yu E; Lee YJ
Cancer; 2013 Jun; 119(12):2239-46. PubMed ID: 23564564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
